NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

As far as the 99 vs 232 OS endpoint.

You want to assert that found LTFU explain the data. Serious issues on your math (discussed later) but the main problem is you are just speculating there is some significant effect resulting from "found" patients.

I am going with the data so far, assuming no unknown bias. Further, you can not ignore NWBO's failure to disclose the data. That is such a huge issue that I fall to see how anybody can ignore it.

Anyway, back to the LTFUs. I am talking from recollection here, so please feel free to correct any specific numbers.

What we know is that there were something like 12-18 known LTFUs in the 2017 blended dataset (Senti's count). There are something like 8 LTFUs in the published 2020 223 data (stat estimate based on At Risk vs OS %). There were 6 dropouts in the 2020 99 patient set (LL).

I fail to see why there is any evidence in this that the early LTFUs have been found. What is worse, there is no evidence of any bias in the distribution. Looks like about 2-1.

Sure, maybe a couple patients. And even then you do not know how soon the evented. Not going to change much.